Alnylam Pharmaceuticals: SEC Filings Confirm No Change in Control or Governance
Alnylam’s Nov 2026 filings reveal modest institutional gains and routine director purchases—no control shifts, just continued SEC‑compliant transparency.
3 minutes to read








